EP2299976A4 - Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders - Google Patents

Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders

Info

Publication number
EP2299976A4
EP2299976A4 EP09835529.0A EP09835529A EP2299976A4 EP 2299976 A4 EP2299976 A4 EP 2299976A4 EP 09835529 A EP09835529 A EP 09835529A EP 2299976 A4 EP2299976 A4 EP 2299976A4
Authority
EP
European Patent Office
Prior art keywords
treatment
methods
controlled release
sensory cell
auris sensory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09835529.0A
Other languages
German (de)
French (fr)
Other versions
EP2299976A2 (en
Inventor
Jay Lichter
Benedikt Vollrath
Andrew M Trammel
Sergio G Durón
Fabrice Piu
Luis A Dellamary
Qiang Ye
Carl Lebel
Michael Christopher Scaife
Jeffrey P Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Otonomy Inc
Original Assignee
University of California
Otonomy Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0907070A external-priority patent/GB2461962B/en
Priority claimed from US12/504,553 external-priority patent/US8496957B2/en
Application filed by University of California, Otonomy Inc filed Critical University of California
Publication of EP2299976A2 publication Critical patent/EP2299976A2/en
Publication of EP2299976A4 publication Critical patent/EP2299976A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP09835529.0A 2008-12-22 2009-12-10 Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders Withdrawn EP2299976A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US14003308P 2008-12-22 2008-12-22
US16023309P 2009-03-13 2009-03-13
US16481209P 2009-03-30 2009-03-30
GB0907070A GB2461962B (en) 2008-07-25 2009-04-24 Slow release NMDA receptor antagonist for otic disorders
US17442109P 2009-04-30 2009-04-30
US12/504,553 US8496957B2 (en) 2008-07-21 2009-07-16 Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
PCT/US2009/067552 WO2010074992A2 (en) 2008-12-22 2009-12-10 Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders

Publications (2)

Publication Number Publication Date
EP2299976A2 EP2299976A2 (en) 2011-03-30
EP2299976A4 true EP2299976A4 (en) 2014-07-23

Family

ID=42288363

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09835529.0A Withdrawn EP2299976A4 (en) 2008-12-22 2009-12-10 Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders

Country Status (6)

Country Link
EP (1) EP2299976A4 (en)
JP (4) JP6013736B2 (en)
CN (2) CN102112111A (en)
AU (1) AU2009330458B2 (en)
CA (1) CA2732686C (en)
WO (1) WO2010074992A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6170047B2 (en) 2011-08-31 2017-07-26 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド Apoptosis-targeting nanoparticles
US10416167B2 (en) 2012-02-17 2019-09-17 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
WO2015138992A1 (en) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
WO2016019000A1 (en) * 2014-07-29 2016-02-04 Otonomy, Inc. Otic formulations for the treatment of ceruminosis
EP3331547A4 (en) 2015-08-05 2019-08-21 Children's Medical Center Corporation Compositions with permeation enhancers for drug delivery
CN109475518A (en) 2016-05-18 2019-03-15 桑得医药品公司 The treatment of Meniere disease
EP3512501A4 (en) * 2016-09-14 2020-04-29 Children's Medical Center Corporation Compositions with permeation enhancers for drug delivery
KR20240074912A (en) * 2016-09-16 2024-05-28 바이킹 테라퓨틱스 인코포레이티드 Method of reducing thyroid-associated side effects
KR20190104524A (en) 2016-11-21 2019-09-10 바이킹 테라퓨틱스 인코포레이티드 Treatment method of sugar accumulation disease
CN110099999B (en) * 2016-12-22 2022-12-27 南京大学 Animal model for hearing loss syndrome and treatment method thereof
EP3634426A4 (en) 2017-06-05 2021-04-07 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EA202091979A1 (en) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. CRYSTALLINE FORMS AND METHODS FOR OBTAINING CRYSTALLINE FORMS OF COMPOUNDS
JPWO2020045162A1 (en) * 2018-08-30 2021-08-12 学校法人慶應義塾 Carrier for drug delivery
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0551626A1 (en) * 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
WO2000007603A2 (en) * 1998-08-04 2000-02-17 Madash Llp End modified thermal responsive hydrogels
US20040101560A1 (en) * 2002-11-27 2004-05-27 Sawchuk Ronald J. Methods and compositions for applying pharmacologic agents to the ear
US20070015727A1 (en) * 2002-09-06 2007-01-18 Jean-Luc Puel Delivery of modulators of glutamate-mediated neurotransmission to the inner ear
WO2007038949A1 (en) * 2005-09-28 2007-04-12 Auris Medical Ag Pharmaceutical compositions for the treatment of inner ear disorders
WO2009132050A2 (en) * 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
WO2009139924A2 (en) * 2008-05-14 2009-11-19 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of otic disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
US6998137B2 (en) * 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
US6589549B2 (en) * 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
CA2497867A1 (en) * 2002-09-06 2004-03-18 Durect Corporation Delivery of modulators of glutamate-mediated neurotransmission to the inner ear
JP2005220070A (en) * 2004-02-05 2005-08-18 Medgel Corp Bioabsorbable polymer hydrogel preparation for neurotization and neuroprotection
US20060063802A1 (en) * 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) * 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
JP2006111585A (en) * 2004-10-15 2006-04-27 Mebiol Kk Sustained release composition and sustained releasing method therefor
JP2008531726A (en) * 2005-03-04 2008-08-14 ニューロシステック コーポレイション Improved gacyclidine formulation
TW200808360A (en) * 2006-04-13 2008-02-16 Alcon Mfg Ltd RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0551626A1 (en) * 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
WO2000007603A2 (en) * 1998-08-04 2000-02-17 Madash Llp End modified thermal responsive hydrogels
US20070015727A1 (en) * 2002-09-06 2007-01-18 Jean-Luc Puel Delivery of modulators of glutamate-mediated neurotransmission to the inner ear
US20040101560A1 (en) * 2002-11-27 2004-05-27 Sawchuk Ronald J. Methods and compositions for applying pharmacologic agents to the ear
WO2007038949A1 (en) * 2005-09-28 2007-04-12 Auris Medical Ag Pharmaceutical compositions for the treatment of inner ear disorders
WO2009132050A2 (en) * 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
WO2009139924A2 (en) * 2008-05-14 2009-11-19 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of otic disorders

Also Published As

Publication number Publication date
JP2017160232A (en) 2017-09-14
CN106344495A (en) 2017-01-25
CN102112111A (en) 2011-06-29
JP6013736B2 (en) 2016-10-25
AU2009330458A1 (en) 2010-07-01
WO2010074992A2 (en) 2010-07-01
CA2732686A1 (en) 2010-07-01
JP2012513394A (en) 2012-06-14
WO2010074992A3 (en) 2010-10-21
AU2009330458B2 (en) 2013-08-22
JP2015164943A (en) 2015-09-17
EP2299976A2 (en) 2011-03-30
CA2732686C (en) 2017-10-03
JP2018138585A (en) 2018-09-06
JP6207093B2 (en) 2017-10-04

Similar Documents

Publication Publication Date Title
EP2299976A4 (en) Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
IL266471A (en) Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
ZA201007482B (en) Controlled release corticosteriod compositions and methods for the treatment of otic disorders
IL210720A0 (en) Controlled release antimicrobial compositions and methods for the treatment of otic disorders
IL251768A0 (en) Auris formulations for treating otic diseases and conditions
HRP20182135T1 (en) Compositions and methods for treating ige-mediated disorders
HK1254745A1 (en) Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2293800A4 (en) Compositions and methods for treatment of ear disorders
EP2170309A4 (en) Methods and compositions for treating disorders
EP2361089A4 (en) Compositions and methods for the treatment of altered -synuclein function
EP2552433A4 (en) Compositions and methods for the treatment of somatosensory disorders
EP2120580A4 (en) Compositions and methods for the treatment of metabolic disorders
EP2224987A4 (en) Devices and methods for suppression of tinnitus
EP2176283A4 (en) Methods and compositions for treating brain diseases
GB201001047D0 (en) Methods and compositions for the treatment of neurological disorders
EP2306975A4 (en) Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
IL209032A0 (en) Compositions and methods for treating digestive disorders
IL210385A (en) Ophthalmic devices and method of forming the same
IL226203A0 (en) Use of pde7 inhibitors and compositions comprising the same for treating addiction and impulse-control disorders
HK1162366A1 (en) Devices and methods for treating and or preventing diseases
GB2461186B (en) Controlled release corticosteroid compositions and methods for the treatment of otic disorders
EP2437768A4 (en) Compounds and methods for treating bone disorders and controlling weight
EP2370087A4 (en) Methods and compositions for the treatment of fluid retention disorders
EP2437771A4 (en) Compositions and methods modulating mg29 for the treatment of diabetes
EP2300044A4 (en) Methods and compositions for the management of pain using omega-conotoxins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20101221

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

A4 Supplementary search report drawn up and despatched

Effective date: 20140624

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/34 20060101ALI20140617BHEP

Ipc: A61K 31/045 20060101ALI20140617BHEP

Ipc: A61K 47/38 20060101ALI20140617BHEP

Ipc: A61K 9/127 20060101ALI20140617BHEP

Ipc: A61P 27/16 20060101ALI20140617BHEP

Ipc: A61K 9/06 20060101AFI20140617BHEP

Ipc: A61K 9/16 20060101ALI20140617BHEP

17Q First examination report despatched

Effective date: 20150601

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: OTONOMY, INC.

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200701